Metraipolis › archive › dc_cd1f86e615c0

From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME — Europe PMC PMID:42795729

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42795729
DOI
10.3390/jcm15186956
License (as archived)
solo-consultazione
Archived
2026-10-15T22:59:20.370Z
SHA-256 of the archived text
e4924a358857414fef48059e1bec00f91dea7e0d0acbd1f84e26cc5c4e824ec5
Stable URL of this page
https://metraipolis.com/documento/dc_cd1f86e615c0

How to cite

From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME — Europe PMC PMID:42795729 — Europe PMC (en), https://europepmc.org/article/MED/42795729 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cd1f86e615c0 (Metraipolis archive dc_cd1f86e615c0, sha256 e4924a358857414fef48059e1bec00f91dea7e0d0acbd1f84e26cc5c4e824ec5)
BibTeX
@misc{dccd1f86e615c0,
  title = {From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME — Europe PMC PMID:42795729},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42795729},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cd1f86e615c0; sha256 e4924a358857414fef48059e1bec00f91dea7e0d0acbd1f84e26cc5c4e824ec5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42795729. Agents can read the archived copy with the MCP tool read_document.